Development of fibrinogen gamma-chain peptide-coated, adenosine diphosphate-encapsulated liposomes as a synthetic platelet substitute

Journal of Thrombosis and Haemostasis : JTH
Yosuke OkamuraMakoto Handa

Abstract

The dodecapeptide HHLGGAKQAGDV (H12), corresponding to the fibrinogen gamma-chain carboxy-terminal sequence (gamma 400-411), is a specific binding site of the ligand for platelet GPIIb/IIIa complex. We have evaluated H12-coated nanoparticles (polymerized albumin or liposome) as platelet function-supporting synthetic products. To strengthen the hemostatic ability of H12-coated particles as a platelet substitute, we exploited installation of a drug delivery function by encapsulating adenosine diphosphate (ADP) into liposomes [H12-(ADP)-liposomes]. Via selective interaction with activated platelets through GPIIb/IIIa, H12-(ADP)-liposomes were capable of augmenting agonist-induced platelet aggregation by releasing ADP in an aggregation-dependent manner. When intravenously injected into rats, liposomes were readily targeted to sites of vascular injury as analyzed on computed tomography. In fact, comparable to fresh platelets, liposomes exhibited considerable hemostatic ability for correcting prolonged bleeding time in a busulphan-induced thrombocytopenic rabbit model. In addition, the liposomes showed no activating or aggregating effects on circulating platelets in normal rabbits. H12-(ADP)-liposome may thus offer a promising platel...Continue Reading

References

Feb 1, 1992·European Journal of Clinical Investigation·G Agam, A A Livne
Jul 1, 1987·The Journal of Clinical Investigation·J A WareE W Salzman
Jan 1, 1996·Annual Review of Cell and Developmental Biology·E Ruoslahti
Feb 21, 1997·The Journal of Biological Chemistry·K SuehiroE F Plow
Jul 23, 2003·Journal of Thrombosis and Haemostasis : JTH·M A Blajchman
Dec 19, 2003·Biochemical and Biophysical Research Communications·Shinji TakeokaYasuo Ikeda
Jun 4, 2004·Thrombosis and Haemostasis·Takako Nishiya, Chikaho Toma
Sep 10, 2005·Journal of Thrombosis and Haemostasis : JTH·S HeptinstallA E White
Mar 17, 2007·Artificial Cells, Blood Substitutes, and Immobilization Biotechnology·Arthur P Bode, Thomas H Fischer

❮ Previous
Next ❯

Citations

Jul 23, 2003·Research in Developmental Disabilities·Teresa Iacono, Robert Davis
Mar 25, 2011·Drug Metabolism Reviews·Kazuaki TaguchiMasaki Otagiri
Sep 19, 2012·International Journal of Pharmaceutics·Koji TokutomiNaoto Oku
Mar 6, 2015·Science Translational Medicine·Leslie W ChanSuzie H Pun
Oct 28, 2016·British Journal of Haematology·Michael J R DesboroughSimon J Stanworth
Sep 30, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Yosuke OkamuraShinji Takeoka
Nov 26, 2015·Advanced Drug Delivery Reviews·Jacob W MyersonVladimir R Muzykantov
Oct 4, 2013·Nanoscale·Margaret Lashof-SullivanErin Lavik
Dec 7, 2013·Journal of Biomedical Materials Research. Part a·Adam M BehrensPeter Kofinas
Oct 2, 2019·Journal of Thrombosis and Haemostasis : JTH·Hunter B Moore, Keith B Neeves
Sep 13, 2013·Nihon Jibiinkoka Gakkai kaiho·Yosuke Okamura, Shinji Takeoka
Apr 11, 2018·World Journal of Gastroenterology : WJG·Kazuhiro TakahashiNobuhiro Ohkohchi
Nov 14, 2019·Surgery Today·Kazuhiro TakahashiNobuhiro Ohkohchi
Nov 23, 2017·Advanced Materials·DaShawn A HickmanAnirban Sen Gupta
Apr 30, 2019·Frontiers in Bioengineering and Biotechnology·Suyun Janet TanShinji Takeoka
Jan 13, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Jan Simak, Silvia De Paoli
Jan 23, 2021·RSC Medicinal Chemistry·Snehasish GhoshRituparna Sinha Roy
Feb 25, 2019·Advanced Drug Delivery Reviews·Marie RouquettePatrick Couvreur
Jun 3, 2021·Journal of Clinical Medicine·Annina CapraruBehrouz Mansouri Taleghani
Mar 25, 2015·Bioconjugate Chemistry·Leslie W ChanSuzie H Pun
Jun 28, 2019·Bioconjugate Chemistry·Ashley C BrownSarah E Stabenfeldt
May 23, 2012·Bioconjugate Chemistry·Madhumitha RavikumarAnirban Sen Gupta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.